We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
 

Latest News

Hybrigenics and Servier Enter into a License and Research Collaboration Agreement
News   Oct 10, 2011

Hybrigenics will receive EUR four million over three years to identify new deubiquitinating enzymes and screen their inhibitors, and is further eligible to success milestones.

READ MORE

Alpharadin Significantly Improves Overall Survival for CRPC Patients with Bone Metastases
News   Oct 10, 2011

First presentation of full ALSYMPCA phase III data as part of Presidential Session featuring Best and Late-Breaking Abstracts at 2011 EMCC.

READ MORE

PharmaGap Files Provisional Patent Application for Liposomal Formulations of GAP-107B8
News   Oct 05, 2011

Company files two provisional patent applications with USPTO during 2011 to date.

READ MORE

New Technique Identifies First Events in Tumor Development
News   Oct 05, 2011

NIH-funded study provides insight to the earliest stages of some cancers.

READ MORE

Journal of Immunology Publishes Study of Cleveland BioLabs' Drug CBLB502 in Acute Renal Ischemic Failure
News   Oct 04, 2011

The study analyzes the ability of CBLB502 to attenuate injury in a murine model of acute ischemic renal failure.

READ MORE

Warnex and deCODE Genetics Announce Exclusive Distribution Agreement
News   Oct 04, 2011

Agreement for deCODE's disease risk tests in Canada.

READ MORE

Modeling Cancer Using Ecological Principles
News   Oct 04, 2011

New research uses Tilman model of competition between invasive species to study the metastasis of prostate cells into bone.

READ MORE

Tyrosine Kinase Inhibitors Take Larger Share of Cancer Drug Sales
News   Oct 03, 2011

Gleevac and Nexavar represent the fastest growing segment in the market for cancer treatments.

READ MORE

Cleveland BioLabs and RUSNANO Enter Into Agreement to Form New Joint Venture
News   Sep 27, 2011

Agreement to provide funding for Panacela Labs, Inc. which will develop a portfolio of new preclinical drug candidates.

READ MORE

Adaptimmune Announces New Board Appointments
News   Sep 26, 2011

Dr Jonathan Knowles joins the Board as a non-executive director and Dr Helen Tayton-Martin, Adaptimmune’s Chief Operating Officer, becomes an executive director both with immediate effect.

READ MORE

 
Advertisement